Inappropriate Medication in the Geriatric Population

Earn CME/CE in your profession:


Continuing Education Activity

Potentially inappropriate medications are drugs that pose a risk of causing adverse events. Many tools, such as the American Geriatrics Society Beers Criteria®, have been developed to assess potentially inappropriate medications in the geriatric population. The latest version of the AGS Beers Criteria® was revised in 2019 to assist practicing clinicians in outpatient, acute, and institutional settings. It includes medications evaluated in 5 main categories: drugs to avoid, drugs to use with caution, drug-drug interactions, medications to avoid in particular clinical situations, and dosage according to kidney function. This activity illustrates the main issues concerning inappropriate medication use in the geriatric population and highlights the interprofessional team's role in improving patient care.

Objectives:

  • Explain the importance of inappropriate medication use in the geriatric population and summarize the risks associated with inappropriate medication use.
  • Describe the basis, utilization, advantages, and limitations of the AGS Beers Criteria.
  • Outline relevant strategies to assess geriatric patients with potentially inappropriate medications.
  • Review the interprofessional interventions for evaluating and preventing inappropriate medication use in older adults.

Introduction

Potentially inappropriate medications (PIM) can be defined as drugs that pose an increased risk of causing adverse events.[1]

The American Geriatrics Society Beers Criteria® is a set of recommendations for avoiding potentially inappropriate medications in the geriatric population.[2] Initially published in 1991, the AGS Beers Criteria® has been periodically updated to provide more accurate and practical guidelines for healthcare providers.[3][4][1] The AGS Beers Criteria® is consistently revised by an interprofessional team utilizing an evidence-based approach.[3][5]

The latest version of the AGS Beers Criteria® was written in 2019 to assist practicing clinicians in outpatient, acute, and institutional settings. It includes medications evaluated in 5 main categories: drugs to avoid, drugs to use with caution, drug-drug interactions, medications to avoid in particular clinical situations, and dosage according to kidney function.[3]

The AGS Beers Criteria® works as a guideline for practitioners to improve prescriptions, outcomes, and quality of care. Although this list is a comprehensive guide for clinicians, nurses, pharmacists, patients, and their families, it is designed to complement clinical judgment as each clinical scenario is unique.[3]

This review aims to present the main issues of concern, clinical significance, and interprofessional aspects of the AGS Beers Criteria®.

Function

Rationale: Potentially Inappropriate Medication

Polypharmacy is associated with an increased incidence of adverse drug events, decreased functional status, and increased healthcare costs. A relationship between PIM and multiple geriatric syndromes (e.g., falls, cognitive decline, urinary retention) has been established. Adverse effects are one of the leading causes of hospitalization in geriatric patients in the United States and Canada.[6]

Explicit tools such as the AGS Beers Criteria® and STOPP/START criteria are designed to reduce complications caused by PIM. Nonetheless, inappropriate prescriptions are still common, with several studies demonstrating that around half of the geriatric population takes at least one medication included in these lists.[7][8]

The use of multiple medications, long durations of treatment, and shared mechanisms of action, are associated with higher morbidity, particularly regarding falls and functional capacity. Drugs such as diuretics and other antihypertensives, sedatives, and antipsychotics contribute to the high incidence of adverse effects. Moreover, there is an important correlation between polypharmacy and frailty.[9][10][11]

Although an objective reduction in mortality or improvement in quality of life is yet to be proven, it is understood that addressing polypharmacy and optimizing pharmacological treatment contribute to better patient outcomes. The ongoing POLITE-RCT trial attempts to prove this relationship directly via critical primary and secondary interprofessional interventions.[6][12]

Issues of Concern

Epidemiology

The prevalence of potentially inappropriate medication use in the geriatric population varies widely depending on geographical, institutional, cultural, and idiosyncratic factors.[13] Studies report that around 40% of adults older than 65 years old are prescribed at least one medication included in the AGS Beers Criteria®.[4] Antianxiety (benzodiazepines) and antidepressant (selective serotonin reuptake inhibitors and tricyclic antidepressants) drugs are the most commonly included, particularly in nursing homes and long-term care facilities.[13][14]

The most important predictor for PIM use is polypharmacy, which is present in up to 91% of long-term care facilities patients. Other factors, such as female sex and comorbidity, are associated with PIM risks.[1][15][14] Dementia is associated with an 11% increase in PIM use.[3]

Aging, Pharmacokinetics, and Pharmacodynamics

The epidemiological transition has led to an aging population, with a significant increase in chronic conditions and a need for geriatric care. Older adults are at increased risk for adverse drug effects due to comorbidities and changes in the pharmacokinetics and pharmacodynamics associated with aging.[6] Until recent years, clinical trials failed to include significant numbers of geriatric patients, and results were not validated for all populations.[16]

The main age-related changes in pharmacokinetics are a decrease in first-pass metabolism, variations in the volume of distribution due to sarcopenia, and progressive renal function decline. These and other disease-related changes make drug responses challenging to predict. These factors vary from patient to patient and are not linearly related to age or disease progression. Therefore, drug administration should be individualized, considering goals, indications, and expectations.[16]

Polypharmacy

Polypharmacy is classically defined as the use of 5 or more medications by a single patient in a chronic manner. However, utilizing a numerical cutoff does not account for many factors involving this concept, and thus qualitative definitions should be considered. Polypharmacy includes using multiple inappropriate, unwarranted, and harmful medications.[16][17]

Medication appropriateness encompasses adequacy, cost-effectiveness, the patient's preferences, comorbidities, cognitive states, and treatment goals. Patients with multiple comorbidities, attending physicians, and residing in assisted-living facilities are at a higher risk of suffering from polypharmacy.[15] 

The Prescribing Cascade

The prescribing cascade is a term coined in the late 20th Century by Rochon and Gurwitz; it entails the utilization of one or more drugs to prevent or treat the side effects caused by another medication. For instance, when prescribing a non-steroidal anti-inflammatory drug (NSAID), physicians often add a proton-pump inhibitor to prevent gastrointestinal bleeding; or when using opioids to treat pain, a laxative is given to treat opioid-induced constipation. The prescribing cascade should be avoided when possible, considering the risks and benefits of adding multiple medications to a patient's pill burden.[15][16]

Some consequences of polypharmacy and the prescribing cascade are provoking drug-drug interactions, potentiation of adverse effects, frailty, geriatric syndromes, cost burden, and negative outcomes.[16]

Inappropriate Prescriptions

The spectrum of inadequate drug prescriptions ranges from misprescribing to underprescribing and overprescribing. Misprescription occurs when the risk of adverse effects of medication significantly outweighs its clinical benefits, including incorrect dosing or drug combinations. Underprescription is the omission of an indicated drug. Overprescription is the introduction of a drug not indicated for treating a condition.[1][5]

Awareness and Prevention

The relevance of the AGS Beers Criteria® relies on professional awareness. Many approaches have been described to reduce the use of PIM, to reach the goal of informed, safer prescribing practices. Explicit and implicit criteria should be utilized to assess patients holistically.[5]

The AGS Beers Criteria® names potentially, not definitively, inappropriate medications and should be applied with a comprehensive understanding of each patient's clinical scenario and the medication in question.[4][3]

A comprehensive geriatric assessment should be performed when possible, evaluating the individual's functional, cognitive, social, and health status. In addition, automatized warnings and reviews could be implemented in digital health records to address potential mistakes.[5][18]

Comprehensive medication monitoring and pharmacovigilance are innovative strategies that prevent adverse drug effects. Implementing these systems, which physician assistants, students, and other healthcare professionals can track at discharge and in the ambulatory setting, leads to further awareness among attending physicians.[16]

Clinical Significance

How to Apply the AGS Beers Criteria®?

The AGS Beers Criteria® evaluates five aspects of PIM: drugs to avoid, drugs to use with caution, drug interactions, medications to avoid in particular situations, and dosage according to kidney function. These aspects should be considered when prescribing single or multiple drug regimens in older adults.[3]

There are seven key points to apply the AGS Beers Criteria® with real-world judgment, entitled "Using Wisely," which include utilizing the criteria as guidelines for a patient-centered approach.[19][20] The seven key points are as follows:

Key principles to guide optimal use of the American Geriatrics Society Beers Criteria®

1. Medications in the 2019 AGS Beers Criteria® are potentially inappropriate, not definitely inappropriate.

2. Read the rationale and recommendations statements for each criterion. The caveats and guidance listed there are important.

3. Understand why medications are included in the AGS Beers Criteria®, and adjust your approach to those medications accordingly.

4. Optimal application of the AGS Beers Criteria® involves identifying potentially inappropriate medications and, where appropriate, offering safer nonpharmacologic and pharmacologic therapies.

5. The AGS Beers Criteria® should be a starting point for a comprehensive process of identifying and improving medication appropriateness and safety.

6. Access to medications included in the AGS Beers Criteria® should not be excessively restricted by prior authorization and/or health plan coverage policies.

7. The AGS Beers Criteria® are not equally applicable to all countries.

Adapted with permission from Steinman MA, Fick DM. Using Wisely: A reminder on how to properly use the American Geriatrics Society Beers Criteria®.[19]

Aspects to Evaluate in a Medical Visit

The assessment and evaluation of patients in an integral, multi-dimensional fashion is necessary to avoid adverse drug events. Optimal medication prescription is paramount when treating older adults. Many protocols, such as the Assess, Review, Minimize, Optimize, Reassess (ARMOR) and the Prescribing Optimization Method (POM), attempt to standardize and guide these processes. However, these have not been validated.[17]

A stepwise approach to treatment implementation is recommended. There are several key points to evaluate when encountering these situations to avoid inappropriate prescriptions.[17][16] These include:

  • First, is there a clear indication for administering the medication?
  • Do the benefits of the drug outweigh the potential harms?
  • Do any of the medicines present significant interactions?
  • Is the indicated duration of treatment appropriate?
  • Are there any duplicated drugs?
  • Is there a need for renal-adjusted dosage?
  • Is there a non-pharmacological alternative to avoid PIM?
  • What is the patient's functional status?
  • What are the patient's preferences?
  • Is the patient adherent to their treatment?

These questions are helpful when assessing PIM and implementing prescription management programs. The patient must be involved in decision-making.[16]

Some helpful strategies to prevent adverse events include monitoring drug efficacy, assessing drug-drug interactions, avoiding overprescription, and periodically monitoring a patient's pharmacological treatment.

Other essential aspects of assessing are reviewing adherence and dosage formulations. For example, certain patients might chew, spit or combine their medication with food, affecting effectiveness. Moreover, patients with swallowing difficulties might find it challenging to take their medications, and alternatives should be offered. Often, herbal treatments and over-the-counter medications are forgotten and might contribute to unexpected events.[16]

Medication Reconciliation

Medication reconciliation is another technique for evaluating polypharmacy and appropriate prescriptions without sacrificing time. It entails asking the patients to bring a list of all their medications or to bring the actual bottles (also known as the brown bag assessment) to a consultation. This practice is often very revealing and results in discovering potential risks for medication errors, including duplicate bottles of the same medication at different dosages, discovering medications prescribed by other providers, and medications the patient forgot to mention as they may use them intermittently. The American Geriatrics Society recommends only prescribing new drugs after reviewing all of a patient's medications.[15]

Deprescribing

Deprescribing is a necessary intervention that reduces harm and prevents adverse drug events; it is defined as reducing or discontinuing a medication. Treatment efficiency and minimal effective dosage are the goals of deprescribing.[21][15]

This process should be implemented whenever necessary, considering the evidence, patient preferences, and potential risks and benefits. Deprescribing should be seen as therapeutic, not as a harmful intervention. Interprofessional communication is essential to promote patient and provider confidence and achieve treatment goals.[21][22]

Some useful tools for safely deprescribing are the Choosing Wisely Initiative and the Canadian Deprescribing Network. Both aim to optimize treatments and reduce PIM use.[22] Another useful tool is the ACB Calculator, an online calculator that can quantify the anticholinergic burden of multiple medications, individually and in combination, and suggest safer alternatives.[23]

Deprescribing should be systematically implemented, reducing patient hesitancy and improving acceptance.[15]

Other Issues

Limitations to the AGS Beers Criteria®

The AGS Beers Criteria® complements clinical judgment and decision-making and should not be used independently to add or remove medications for patients. Treatment should be individualized, understanding that patients are complex and conditions differ between individuals.[3]

The AGS Beers Criteria® does not always apply to hospitalized and palliative care patients. Risk-benefit ratios vary in these settings, and there are innumerable scenarios to consider.[3][4]

Finally, the AGS Beers Criteria® was validated using evidence from the United States and is not necessarily applicable in all countries.[3]

Enhancing Healthcare Team Outcomes

The AGS Beers Criteria® was developed to be utilized in an interprofessional, patient-centered approach to avoid adverse drug events and assess the prescription of PIM. Clinicians, pharmacists, nurses, and other professionals should be involved in the integral care of geriatric patients.[3]

Several studies have shown that using real-world data based on direct measurements improves patient outcomes and reduces adverse drug events. Databases such as FAERS, WHO VigiBase, and the SYMPATHY Project provide useful information for implementing safe prescribing strategies.[9][6][10]

Physicians play an essential role in prescriptions. Nonetheless, it is often challenging for medical professionals to monitor patients' behaviors and global health. Nurses are better positioned to follow patients and understand changes in health status closely. Pharmacists have a deep understanding of medications.[24] 

In a study conducted in Malaysia, awareness of the AGS Beers Criteria® was less than 40% among pharmacists, meaning that prescriptions were filled without further assessment. Interdisciplinary education and familiarity with the AGS Beers Criteria® are crucial to utilizing system-based review and reducing PIM prescriptions. Promoting pharmacist review of medications, assuming their familiarity with the AGS Beers Criteria®, is a simple intervention that could reduce mistakes.[25]

The Finnish Interprofessional Medication Assessment was a randomized controlled trial that compared adverse drug events when assessing medications with an interprofessional team versus a conventional approach. The intervention resulted in a statistically significant decrease in adverse events.[26] Another study showed that when utilizing multiple tools to assess medications and utilizing a pharmacist-led deprescribing approach, the identification of PIM increased considerably.[22]

When collaboration is encouraged, medication management is simplified, and risks are minimized.[24] Physicians should be in constant, reciprocal communication with patients and other professionals. Adequate care transfer helps address barriers and limitations that could harm patients.[6]

Appropriately prescribing medications is a key intervention to improve patient outcomes. Medical knowledge is not sufficient to guarantee the elimination of harmful medications. Interprofessional collaboration is essential to achieve the goals of care. Prescriber education, feedback and auditing, and clinical decision support tools are strategies that should be systematically implemented to improve healthcare practices.[24][21][20] [Level 2]


Details

Editor:

Caroline Schoo

Updated:

11/19/2022 9:59:09 PM

References


[1]

Abdelwahed AA,El-Dahiyat F,Aljawamis D,Al Ajimi J,Bin Rafeea KJ, Potentially inappropriate medications in older adults according to Beers criteria 2019: Prevalence and risk factors. International journal of clinical practice. 2021 Nov;     [PubMed PMID: 34378294]


[2]

Viana SSC,Souza NPDS,Aliberti MJR,Jacob-Filho W, Use of potentially inappropriate medications and adverse events in older outpatients with acute conditions. Einstein (Sao Paulo, Brazil). 2022;     [PubMed PMID: 35792759]


[3]

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel., American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Apr;     [PubMed PMID: 30693946]


[4]

By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel., American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015 Nov;     [PubMed PMID: 26446832]


[5]

O'Connor MN,Gallagher P,O'Mahony D, Inappropriate prescribing: criteria, detection and prevention. Drugs     [PubMed PMID: 22642779]


[6]

Baruth JM,Gentry MT,Rummans TA,Miller DM,Burton MC, Polypharmacy in older adults: the role of the multidisciplinary team. Hospital practice (1995). 2020 Mar;     [PubMed PMID: 31900000]


[7]

Lund BC,Carnahan RM,Egge JA,Chrischilles EA,Kaboli PJ, Inappropriate prescribing predicts adverse drug events in older adults. The Annals of pharmacotherapy. 2010 Jun;     [PubMed PMID: 20460558]


[8]

Suehs BT,Davis C,Ng DB,Gooch K, Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder. Drugs     [PubMed PMID: 28540648]


[9]

Shao Q,Xu Y,Li M,Chu X,Liu W, Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database. European journal of clinical pharmacology. 2021 Aug;     [PubMed PMID: 34170370]


[10]

Shin H,Kim N,Cha J,Kim GJ,Kim JH,Kim JY,Lee S, Geriatrics on beers criteria medications at risk of adverse drug events using real-world data. International journal of medical informatics. 2021 Oct;     [PubMed PMID: 34411951]


[11]

Wolff DT,Adler KA,Weinstein CS,Weiss JP, Managing Nocturia in Frail Older Adults. Drugs     [PubMed PMID: 33230803]


[12]

Löffler C,Drewelow E,Paschka SD,Frankenstein M,Eger J,Jatsch L,Reisinger EC,Hallauer JF,Drewelow B,Heidorn K,Schröder H,Wollny A,Kundt G,Schmidt C,Altiner A, Optimizing polypharmacy among elderly hospital patients with chronic diseases--study protocol of the cluster randomized controlled POLITE-RCT trial. Implementation science : IS. 2014 Oct 6;     [PubMed PMID: 25287853]

Level 1 (high-level) evidence

[13]

Storms H,Marquet K,Aertgeerts B,Claes N, Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: A systematic review. The European journal of general practice. 2017 Dec;     [PubMed PMID: 28271916]

Level 1 (high-level) evidence

[14]

Sharma R,Bansal P,Sharma A,Chhabra M,Bansal N,Arora M, Clonazepam tops the list of potentially inappropriate psychotropic (PIP) medications in older adults with psychiatric illness: A cross-sectional study based on Beers criteria 2019 vs STOPP criteria 2015. Asian journal of psychiatry. 2021 Apr;     [PubMed PMID: 33618072]

Level 2 (mid-level) evidence

[15]

Halli-Tierney AD,Scarbrough C,Carroll D, Polypharmacy: Evaluating Risks and Deprescribing. American family physician. 2019 Jul 1;     [PubMed PMID: 31259501]


[16]

Antimisiaris D,Cutler T, Managing Polypharmacy in the 15-Minute Office Visit. Primary care. 2017 Sep;     [PubMed PMID: 28797369]


[17]

Levy HB, Polypharmacy Reduction Strategies: Tips on Incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria. Clinics in geriatric medicine. 2017 May;     [PubMed PMID: 28364990]


[18]

DeRhodes KH, The Dangers of Ignoring the Beers Criteria-The Prescribing Cascade. JAMA internal medicine. 2019 Jul 1;     [PubMed PMID: 31081879]


[19]

Steinman MA,Fick DM, Using Wisely: A Reminder on How to Properly Use the American Geriatrics Society Beers Criteria{sup}®{/sup}. Journal of gerontological nursing. 2019 Mar 1;     [PubMed PMID: 30789983]


[20]

Steinman MA,Beizer JL,DuBeau CE,Laird RD,Lundebjerg NE,Mulhausen P, How to Use the American Geriatrics Society 2015 Beers Criteria-A Guide for Patients, Clinicians, Health Systems, and Payors. Journal of the American Geriatrics Society. 2015 Dec;     [PubMed PMID: 26446776]


[21]

Earl TR,Katapodis ND,Schneiderman SR,Shoemaker-Hunt SJ, Using Deprescribing Practices and the Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria to Reduce Harm and Preventable Adverse Drug Events in Older Adults. Journal of patient safety. 2020 Sep;     [PubMed PMID: 32809998]


[22]

Whitman A,DeGregory K,Morris A,Mohile S,Ramsdale E, Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2018 Dec;     [PubMed PMID: 29869294]

Level 3 (low-level) evidence

[23]

Villalba-Moreno Á,Alfaro-Lara ER,Sánchez-Fidalgo S,Nieto-Martín MD,Santos-Ramos B, Development of the Anticholinergic Burden Calculator Web Tool. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2017 Sep 1     [PubMed PMID: 28847259]


[24]

Krause O,Wiese B,Doyle IM,Kirsch C,Thürmann P,Wilm S,Sparenberg L,Stolz R,Freytag A,Bleidorn J,Junius-Walker U,HIOPP-3-iTBX study group., Multidisciplinary intervention to improve medication safety in nursing home residents: protocol of a cluster randomised controlled trial (HIOPP-3-iTBX study). BMC geriatrics. 2019 Jan 25;     [PubMed PMID: 30683060]

Level 1 (high-level) evidence

[25]

Foong RTK,Sellappans R,Loo JSE, Awareness of Beers Criteria and knowledge of potentially inappropriate medications among community pharmacists in the Klang Valley, Malaysia. Journal of evaluation in clinical practice. 2020 Feb;     [PubMed PMID: 31168913]


[26]

Auvinen KJ,Räisänen J,Voutilainen A,Jyrkkä J,Mäntyselkä P,Lönnroos E, Interprofessional Medication Assessment has Effects on the Quality of Medication Among Home Care Patients: Randomized Controlled Intervention Study. Journal of the American Medical Directors Association. 2021 Jan;     [PubMed PMID: 32893136]

Level 2 (mid-level) evidence